 | • レポートコード：MRC2-11QY13564 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は急性骨髄性白血病のグローバル市場について調査・分析したレポートです。種類別（化学療法、放射線療法、幹細胞移植、標的療法、その他）市場規模、用途別（病院、小売ドラッグストア、外来診療センター、腫瘍センター、診療所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別急性骨髄性白血病の競争状況、市場シェア ・世界の急性骨髄性白血病市場：種類別市場規模 2015年-2020年（化学療法、放射線療法、幹細胞移植、標的療法、その他） ・世界の急性骨髄性白血病市場：種類別市場規模予測 2021年-2026年（化学療法、放射線療法、幹細胞移植、標的療法、その他） ・世界の急性骨髄性白血病市場：用途別市場規模 2015年-2020年（病院、小売ドラッグストア、外来診療センター、腫瘍センター、診療所） ・世界の急性骨髄性白血病市場：用途別市場規模予測 2021年-2026年（病院、小売ドラッグストア、外来診療センター、腫瘍センター、診療所） ・北米の急性骨髄性白血病市場分析：米国、カナダ ・ヨーロッパの急性骨髄性白血病市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの急性骨髄性白血病市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の急性骨髄性白血病市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの急性骨髄性白血病市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Celgene Corporation、Cephalon、Clavis Pharma、Eisai、Genzyme Corporation、Sunesis Pharmaceuticals、Abbvie、Astellas Pharma、CTI Biopharma Corp ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection.
Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.
Market Analysis and Insights: Global Acute Myeloid Leukemia Market
The global Acute Myeloid Leukemia market size is projected to reach US$ 1344.9 million by 2026, from US$ 1179.5 million in 2020, at a CAGR of 13.0%% during 2021-2026.
Global Acute Myeloid Leukemia Scope and Market Size
Acute Myeloid Leukemia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Acute Myeloid Leukemia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Abbvie
Astellas Pharma
CTI Biopharma Corp
Market segment by Type, the product can be split into
Chemotherapy
Radiation Therapy
Stem Cell Transplant
Targeted Therapy
Others
Market segment by Application, split into
Hospital
Retails Drug Stores
Ambulatory Care Centers
Oncology Centers
Clinics
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Acute Myeloid Leukemia Revenue
1.4 Market by Type
1.4.1 Global Acute Myeloid Leukemia Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Stem Cell Transplant
1.4.5 Targeted Therapy
1.4.6 Others
1.5 Market by Application
1.5.1 Global Acute Myeloid Leukemia Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Retails Drug Stores
1.5.4 Ambulatory Care Centers
1.5.5 Oncology Centers
1.5.6 Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia Market Perspective (2015-2026)
2.2 Global Acute Myeloid Leukemia Growth Trends by Regions
2.2.1 Acute Myeloid Leukemia Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Acute Myeloid Leukemia Historic Market Share by Regions (2015-2020)
2.2.3 Acute Myeloid Leukemia Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Acute Myeloid Leukemia Market Growth Strategy
2.3.6 Primary Interviews with Key Acute Myeloid Leukemia Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia Players by Market Size
3.1.1 Global Top Acute Myeloid Leukemia Players by Revenue (2015-2020)
3.1.2 Global Acute Myeloid Leukemia Revenue Market Share by Players (2015-2020)
3.1.3 Global Acute Myeloid Leukemia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Acute Myeloid Leukemia Market Concentration Ratio
3.2.1 Global Acute Myeloid Leukemia Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia Revenue in 2019
3.3 Acute Myeloid Leukemia Key Players Head office and Area Served
3.4 Key Players Acute Myeloid Leukemia Product Solution and Service
3.5 Date of Enter into Acute Myeloid Leukemia Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Acute Myeloid Leukemia Historic Market Size by Type (2015-2020)
4.2 Global Acute Myeloid Leukemia Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Acute Myeloid Leukemia Market Size by Application (2015-2020)
5.2 Global Acute Myeloid Leukemia Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Acute Myeloid Leukemia Market Size (2015-2020)
6.2 Acute Myeloid Leukemia Key Players in North America (2019-2020)
6.3 North America Acute Myeloid Leukemia Market Size by Type (2015-2020)
6.4 North America Acute Myeloid Leukemia Market Size by Application (2015-2020)
7 Europe
7.1 Europe Acute Myeloid Leukemia Market Size (2015-2020)
7.2 Acute Myeloid Leukemia Key Players in Europe (2019-2020)
7.3 Europe Acute Myeloid Leukemia Market Size by Type (2015-2020)
7.4 Europe Acute Myeloid Leukemia Market Size by Application (2015-2020)
8 China
8.1 China Acute Myeloid Leukemia Market Size (2015-2020)
8.2 Acute Myeloid Leukemia Key Players in China (2019-2020)
8.3 China Acute Myeloid Leukemia Market Size by Type (2015-2020)
8.4 China Acute Myeloid Leukemia Market Size by Application (2015-2020)
9 Japan
9.1 Japan Acute Myeloid Leukemia Market Size (2015-2020)
9.2 Acute Myeloid Leukemia Key Players in Japan (2019-2020)
9.3 Japan Acute Myeloid Leukemia Market Size by Type (2015-2020)
9.4 Japan Acute Myeloid Leukemia Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Acute Myeloid Leukemia Market Size (2015-2020)
10.2 Acute Myeloid Leukemia Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Acute Myeloid Leukemia Market Size by Type (2015-2020)
10.4 Southeast Asia Acute Myeloid Leukemia Market Size by Application (2015-2020)
11 India
11.1 India Acute Myeloid Leukemia Market Size (2015-2020)
11.2 Acute Myeloid Leukemia Key Players in India (2019-2020)
11.3 India Acute Myeloid Leukemia Market Size by Type (2015-2020)
11.4 India Acute Myeloid Leukemia Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Acute Myeloid Leukemia Market Size (2015-2020)
12.2 Acute Myeloid Leukemia Key Players in Central & South America (2019-2020)
12.3 Central & South America Acute Myeloid Leukemia Market Size by Type (2015-2020)
12.4 Central & South America Acute Myeloid Leukemia Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Celgene Corporation
13.1.1 Celgene Corporation Company Details
13.1.2 Celgene Corporation Business Overview
13.1.3 Celgene Corporation Acute Myeloid Leukemia Introduction
13.1.4 Celgene Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020))
13.1.5 Celgene Corporation Recent Development
13.2 Cephalon
13.2.1 Cephalon Company Details
13.2.2 Cephalon Business Overview
13.2.3 Cephalon Acute Myeloid Leukemia Introduction
13.2.4 Cephalon Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.2.5 Cephalon Recent Development
13.3 Clavis Pharma
13.3.1 Clavis Pharma Company Details
13.3.2 Clavis Pharma Business Overview
13.3.3 Clavis Pharma Acute Myeloid Leukemia Introduction
13.3.4 Clavis Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.3.5 Clavis Pharma Recent Development
13.4 Eisai
13.4.1 Eisai Company Details
13.4.2 Eisai Business Overview
13.4.3 Eisai Acute Myeloid Leukemia Introduction
13.4.4 Eisai Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.4.5 Eisai Recent Development
13.5 Genzyme Corporation
13.5.1 Genzyme Corporation Company Details
13.5.2 Genzyme Corporation Business Overview
13.5.3 Genzyme Corporation Acute Myeloid Leukemia Introduction
13.5.4 Genzyme Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.5.5 Genzyme Corporation Recent Development
13.6 Sunesis Pharmaceuticals
13.6.1 Sunesis Pharmaceuticals Company Details
13.6.2 Sunesis Pharmaceuticals Business Overview
13.6.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Introduction
13.6.4 Sunesis Pharmaceuticals Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.6.5 Sunesis Pharmaceuticals Recent Development
13.7 Abbvie
13.7.1 Abbvie Company Details
13.7.2 Abbvie Business Overview
13.7.3 Abbvie Acute Myeloid Leukemia Introduction
13.7.4 Abbvie Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.7.5 Abbvie Recent Development
13.8 Astellas Pharma
13.8.1 Astellas Pharma Company Details
13.8.2 Astellas Pharma Business Overview
13.8.3 Astellas Pharma Acute Myeloid Leukemia Introduction
13.8.4 Astellas Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.8.5 Astellas Pharma Recent Development
13.9 CTI Biopharma Corp
13.9.1 CTI Biopharma Corp Company Details
13.9.2 CTI Biopharma Corp Business Overview
13.9.3 CTI Biopharma Corp Acute Myeloid Leukemia Introduction
13.9.4 CTI Biopharma Corp Revenue in Acute Myeloid Leukemia Business (2015-2020)
13.9.5 CTI Biopharma Corp Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Acute Myeloid Leukemia Key Market Segments
Table 2. Key Players Covered: Ranking by Acute Myeloid Leukemia Revenue
Table 3. Ranking of Global Top Acute Myeloid Leukemia Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Acute Myeloid Leukemia Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Radiation Therapy
Table 7. Key Players of Stem Cell Transplant
Table 8. Key Players of Targeted Therapy
Table 9. Key Players of Others
Table 10. Global Acute Myeloid Leukemia Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Acute Myeloid Leukemia Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Acute Myeloid Leukemia Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Acute Myeloid Leukemia Market Share by Regions (2015-2020)
Table 14. Global Acute Myeloid Leukemia Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Acute Myeloid Leukemia Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Acute Myeloid Leukemia Market Growth Strategy
Table 20. Main Points Interviewed from Key Acute Myeloid Leukemia Players
Table 21. Global Acute Myeloid Leukemia Revenue by Players (2015-2020) (Million US$)
Table 22. Global Acute Myeloid Leukemia Market Share by Players (2015-2020)
Table 23. Global Top Acute Myeloid Leukemia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Myeloid Leukemia as of 2019)
Table 24. Global Acute Myeloid Leukemia by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Acute Myeloid Leukemia Product Solution and Service
Table 27. Date of Enter into Acute Myeloid Leukemia Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 30. Global Acute Myeloid Leukemia Market Size Share by Type (2015-2020)
Table 31. Global Acute Myeloid Leukemia Revenue Market Share by Type (2021-2026)
Table 32. Global Acute Myeloid Leukemia Market Size Share by Application (2015-2020)
Table 33. Global Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 34. Global Acute Myeloid Leukemia Market Size Share by Application (2021-2026)
Table 35. North America Key Players Acute Myeloid Leukemia Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Acute Myeloid Leukemia Market Share (2019-2020)
Table 37. North America Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 38. North America Acute Myeloid Leukemia Market Share by Type (2015-2020)
Table 39. North America Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 40. North America Acute Myeloid Leukemia Market Share by Application (2015-2020)
Table 41. Europe Key Players Acute Myeloid Leukemia Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Acute Myeloid Leukemia Market Share (2019-2020)
Table 43. Europe Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Acute Myeloid Leukemia Market Share by Type (2015-2020)
Table 45. Europe Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Acute Myeloid Leukemia Market Share by Application (2015-2020)
Table 47. China Key Players Acute Myeloid Leukemia Revenue (2019-2020) (Million US$)
Table 48. China Key Players Acute Myeloid Leukemia Market Share (2019-2020)
Table 49. China Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 50. China Acute Myeloid Leukemia Market Share by Type (2015-2020)
Table 51. China Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 52. China Acute Myeloid Leukemia Market Share by Application (2015-2020)
Table 53. Japan Key Players Acute Myeloid Leukemia Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Acute Myeloid Leukemia Market Share (2019-2020)
Table 55. Japan Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Acute Myeloid Leukemia Market Share by Type (2015-2020)
Table 57. Japan Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Acute Myeloid Leukemia Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Acute Myeloid Leukemia Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Acute Myeloid Leukemia Market Share (2019-2020)
Table 61. Southeast Asia Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Acute Myeloid Leukemia Market Share by Type (2015-2020)
Table 63. Southeast Asia Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Acute Myeloid Leukemia Market Share by Application (2015-2020)
Table 65. India Key Players Acute Myeloid Leukemia Revenue (2019-2020) (Million US$)
Table 66. India Key Players Acute Myeloid Leukemia Market Share (2019-2020)
Table 67. India Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 68. India Acute Myeloid Leukemia Market Share by Type (2015-2020)
Table 69. India Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 70. India Acute Myeloid Leukemia Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Acute Myeloid Leukemia Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Acute Myeloid Leukemia Market Share (2019-2020)
Table 73. Central & South America Acute Myeloid Leukemia Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Acute Myeloid Leukemia Market Share by Type (2015-2020)
Table 75. Central & South America Acute Myeloid Leukemia Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Acute Myeloid Leukemia Market Share by Application (2015-2020)
Table 77. Celgene Corporation Company Details
Table 78. Celgene Corporation Business Overview
Table 79. Celgene Corporation Product
Table 80. Celgene Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 81. Celgene Corporation Recent Development
Table 82. Cephalon Company Details
Table 83. Cephalon Business Overview
Table 84. Cephalon Product
Table 85. Cephalon Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 86. Cephalon Recent Development
Table 87. Clavis Pharma Company Details
Table 88. Clavis Pharma Business Overview
Table 89. Clavis Pharma Product
Table 90. Clavis Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 91. Clavis Pharma Recent Development
Table 92. Eisai Company Details
Table 93. Eisai Business Overview
Table 94. Eisai Product
Table 95. Eisai Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 96. Eisai Recent Development
Table 97. Genzyme Corporation Company Details
Table 98. Genzyme Corporation Business Overview
Table 99. Genzyme Corporation Product
Table 100. Genzyme Corporation Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 101. Genzyme Corporation Recent Development
Table 102. Sunesis Pharmaceuticals Company Details
Table 103. Sunesis Pharmaceuticals Business Overview
Table 104. Sunesis Pharmaceuticals Product
Table 105. Sunesis Pharmaceuticals Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 106. Sunesis Pharmaceuticals Recent Development
Table 107. Abbvie Company Details
Table 108. Abbvie Business Overview
Table 109. Abbvie Product
Table 110. Abbvie Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 111. Abbvie Recent Development
Table 112. Astellas Pharma Business Overview
Table 113. Astellas Pharma Product
Table 114. Astellas Pharma Company Details
Table 115. Astellas Pharma Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 116. Astellas Pharma Recent Development
Table 117. CTI Biopharma Corp Company Details
Table 118. CTI Biopharma Corp Business Overview
Table 119. CTI Biopharma Corp Product
Table 120. CTI Biopharma Corp Revenue in Acute Myeloid Leukemia Business (2015-2020) (Million US$)
Table 121. CTI Biopharma Corp Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acute Myeloid Leukemia Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Radiation Therapy Features
Figure 4. Stem Cell Transplant Features
Figure 5. Targeted Therapy Features
Figure 6. Others Features
Figure 7. Global Acute Myeloid Leukemia Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Retails Drug Stores Case Studies
Figure 10. Ambulatory Care Centers Case Studies
Figure 11. Oncology Centers Case Studies
Figure 12. Clinics Case Studies
Figure 13. Acute Myeloid Leukemia Report Years Considered
Figure 14. Global Acute Myeloid Leukemia Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Acute Myeloid Leukemia Market Share by Regions: 2020 VS 2026
Figure 16. Global Acute Myeloid Leukemia Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Acute Myeloid Leukemia Market Share by Players in 2019
Figure 19. Global Top Acute Myeloid Leukemia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Myeloid Leukemia as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Acute Myeloid Leukemia Revenue in 2019
Figure 21. North America Acute Myeloid Leukemia Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Acute Myeloid Leukemia Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Acute Myeloid Leukemia Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Acute Myeloid Leukemia Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Acute Myeloid Leukemia Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Acute Myeloid Leukemia Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Acute Myeloid Leukemia Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
急性骨髄性白血病治療薬の世界市場（～2026年） Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90…- 再発急性骨髄性白血病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Relapsed Acute Myeloid Leukemia Drug Market The global Relapsed Acute Myeloid Leukemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Relapsed Acute Myeloid Leukemia Drug Scop…
- 白血病の世界市場（～2026年） Leukemia is a group ofcancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. High incidence rate of blood cancers and rise in incidence of leukaemia across the globe will drive the leukemia market. Market Analysis and Insights: Global Leukemia Cancer …
- 急性リンパ芽球性白血病薬の世界市場（～2026年） Market Analysis and Insights: Global Acute Lymphoblastic Leukemia Drug Market The global Acute Lymphoblastic Leukemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Acute Lymphoblastic Leukemia Drug Scope and Mar…
- 成人T細胞白血病/リンパ腫治療の世界市場（～2026年） Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative neoplasm caused by human T-lymphotrophic virus 1. In its more common, aggressive forms, ATL carries one of the poorest prognoses of the non-Hodgkin lymphomas. The disease has clinical subtypes (ie, acute, lymphoma, chronic, an…